B7-H4 CAB

**B7-H4 CAB** is a preclinical **conditionally active biologic** directed against **B7-H4**, an immune checkpoint ligand also known as **V-set domain-containing T-cell activation inhibitor 1** that is overexpressed in multiple solid tumors. Public BioAtla pipeline materials identify it as a **next-generation CAB antibody-drug conjugate candidate** rather than an approved or clinically named product. The intended design of BioAtla's CAB platform is tumor-selective, reversible binding that is enhanced in the acidic tumor microenvironment and reduced in normal alkaline tissues, with the goal of improving the therapeutic index of antibody-based cancer therapies. For this candidate, the disclosed intended biology is selective targeting of tumor-associated **B7-H4** for antineoplastic therapy in solid tumors, but specific clinical-stage details, formal nonproprietary naming, exact payload/linker composition, and disease-specific development information have not been clearly publicly disclosed.

Other names

CAB B7-H4B7-H4 conditionally active biologicB-7-H4 conditionally active biologicB 7-H4 conditionally active biologicB7-H4 CAB next generation ADC candidateB-7-H4 CAB next generation ADC candidateB 7-H4 CAB next generation ADC candidate